Catalyst Biosciences Inc expected to post a loss of 44  cents a share - Earnings Preview

Gyre Therapeutics

02/05/2022 19:34

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 4
(estimated). 
    * ​Refinitiv's mean analyst estimate for Catalyst
Biosciences Inc
is for a loss of 44 cents per share. For the same quarter last
year, the company reported a loss of 79 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $15​, above​ its last closing price of $0.48.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -0.59      -0.64     Missed  -8.9
 Sep. 30 2021  -0.67       -0.66      -0.80     Missed  -21.2
 Jun. 30 2021  -0.70       -0.69      -0.64     Beat    7.9​
 Mar. 31 2021  -0.57       -0.58      -0.79     Missed  -36.8
 ​​Dec.        -0.95       -0.86      -0.86     Met     0.3
 31 2020                                                
 Sep. 30 2020  -0.85       -0.81      -0.73     Beat    9.5​
 Jun. 30 2020  -0.77       -0.86      -0.96     Missed  -11.3
 Mar. 31 2020  -0.39       -0.36      -0.28     Beat    23.3
 This summary was machine generated May 2 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated